Aperion Biologics
closedClinical-stage medical device company developing a technique to make animal-tissues usable for human applications.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | $20.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
Aperion Biologics, founded in San Antonio, Texas, in 1996, operated as a medical device company focused on creating alternatives to human-based grafts using animal-based tissue technology. The company's core business involved developing cartilage, soft tissue, and bone replacement products. Its primary technology was designed to prevent immunological rejection of animal tissue in human transplantation, offering solutions for patients with ligament issues.
The company's product pipeline included treatments based on this specialized technology aimed at addressing the need for viable tissue grafts. Aperion Biologics went through several funding stages, including grants and venture capital rounds, to finance its research and development efforts. Records show a Series C2 venture round in May 2011. However, the company's journey concluded, and it is now listed as out of business as of December 2017.
It is important to distinguish this San Antonio-based entity from the Vienna, Austria-based APEIRON Biologics AG. APEIRON Biologics AG is an entirely separate company founded in 2003 that specializes in immuno-oncology and was acquired by Ligand Pharmaceuticals in 2024. The two companies, despite the similar names, have distinct histories, founders, and operational focuses. Keywords: tissue engineering, xenografts, orthopedic repair, soft tissue replacement, bone graft substitute, cartilage repair, immunological rejection, medical devices, animal tissue technology, human transplantation alternatives, ligament repair, therapeutic devices, life sciences, biotechnology, CrossCart